Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ATP + NADH
ADP + NADPH
-
-
-
?
GTP + NAD+
GDP + NADP+
7% of the activity with ATP
-
-
?
CTP + NAD+
CDP + NADP+
-
56% activity compared to ATP
-
-
?
dATP + NAD+
dADP + NADP+
-
99% activity compared to ATP
-
-
?
dITP + NAD+
dIDP + NADP+
-
141% activity compared to ATP
-
-
?
GTP + NAD+
GDP + NADP+
-
162% activity compared to ATP
-
-
?
hexametaphosphate + NAD+
? + NADP+
-
194% activity compared to ATP
-
-
?
ITP + NAD+
IDP + NADP+
-
104% activity compared to ATP
-
-
?
metaphosphate + NAD+
? + NADP+
-
280% activity compared to ATP
-
-
?
tetrapolyphosphate + NAD+
tripolyphosphate + NADP+
-
84% activity compared to ATP
-
-
?
TTP + NAD+
TDP + NADP+
-
87% activity compared to ATP
-
-
?
UTP + NAD+
UDP + NADP+
-
41% activity compared to ATP
-
-
?
additional information
?
-
-
no activity with NAAD, ADP-ribose, adenosine, 5'-AMP, ADP, sphingosine, diacylglycerol, fructose 6-phosphate, trimetaphosphate, tripolyphosphate, phosphoenolpyruvate, and phosphocreatine
-
-
?
ATP + NAD+
ADP + NADP+
-
-
-
?
ATP + NAD+
ADP + NADP+
-
-
-
-
?
ATP + NAD+
ADP + NADP+
-
-
-
?
ATP + NAD+
ADP + NADP+
-
-
-
?
ATP + NAD+
ADP + NADP+
-
-
-
-
?
ATP + NAD+
ADP + NADP+
-
-
-
?
ATP + NAD+
ADP + NADP+
-
-
-
?
ATP + NAD+
ADP + NADP+
synthesis of NADP+
-
-
?
ATP + NAD+
ADP + NADP+
NAD+ kinase is the sole cytosolic enzyme that catalyzes the synthesis of NADP+ from NAD+
-
-
?
ATP + NAD+
ADP + NADP+
the enzyme is required for the de novo synthesis of NADP+ from NAD+
-
-
?
ATP + NAD+
ADP + NADP+
-
-
-
?
ATP + NAD+
ADP + NADP+
-
-
-
-
?
ATP + NAD+
ADP + NADP+
-
-
-
?
ATP + NAD+
ADP + NADP+
-
100% activity
-
-
?
ATP + NAD+
ADP + NADP+
-
preferentially accepts NAD+ as substrate. At 100 micromol, NAD+ is 10fold faster phosphorylated than NADH
-
-
?
ATP + NADH
ADP + NADPH
-
conversion is slow at a NADH concentration of 5 mM. At lower concentrations (50-150 micromol) and particularly when NAD+ is concomitantly present as substrate, NADH becomes farmore efficiently phosphorylated
-
-
?
ATP + NADH
ADP + NADPH
-
10% activity compared to NAD+
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3-acetyl-pyridine adenine dinucleotide
1 mM, 30% inhibition
3-aldehyde-pyridine adenine dinucleotide
1 mM, 32% inhibition
nicotinamide guanine dinucleotide
1 mM, 23% inhibition
nicotinamide hypoxanthine dinucleotide
1 mM, 24% inhibition
nicotinic acid adenine dinucleotide phosphate
1 mM, 37% inhibition
Trifluoperazine
inhibits stimulation by calmodulin
2-(adenosine-8-thio)-N-(3,4-dichlorophenethyl)acetamide
-
-
2-(adenosine-8-thio)-N-(3-bromophenethyl)acetamide
-
-
2-(adenosine-8-thio)-N-(3-chlorophenethyl)acetamide
-
-
2-(adenosine-8-thio)-N-(4-bromophenethyl)acetamide
-
-
2-(adenosine-8-thio)-N-(4-chlorophenethyl)acetamide
-
20% inhibition at 0.5 mM
2-(adenosine-8-thio)-N-phenethylacetamide
-
10% inhibition at 0.4 mM
2-(adenosine-8-thio)-N-[(3-indoyl)ethyl]acetamide
-
20% inhibition at 0.5 mM
2-(adenosine-8-thio)-N-[(5-chloro-3-indoyl)ethyl]acetamide
-
-
2-[(5'-amino-5'-deoxyadenosine)-8-thio]-N-(3,4-dichlorophenethyl)acetamide
-
-
2-[(5'-amino-5'-deoxyadenosine)-8-thio]-N-(3-bromophenethyl)propanamide
-
-
2-[(5'-amino-5'-deoxyadenosine)-8-thio]-N-(4-bromophenethyl)acetamide
-
-
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(2-benzimidazolylethyl)acetamide
-
-
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(2-chloro-5-pyridyl)acetamide
-
-
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(2-naphthylethyl)acetamide
-
-
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(3,4-dichlorophenethyl)acetamide
-
-
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(3-bromobenzyl)acetamide
-
-
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(3-bromophenethyl)acetamide
-
-
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(3-chlorophenethyl)acetamide
-
-
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(3-ethynylphenethyl)acetamide
-
40% inhibition at 0.25 mM
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(3-trifluoromethylphenethyl)acetamide
-
-
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(4-bromophenethyl)acetamide
-
-
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(4-chlorophenethyl)acetamide
-
-
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-phenethylacetamide
-
-
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-phenethylpropanamide
-
-
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-propargylacetamide
-
-
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-[(3-indoyl)ethyl]acetamide
-
-
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-[(4-trifluoromethyl)phenethyl]acetamide
-
-
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-[(5-chloro-3-indoyl)ethyl]acetamide
-
-
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-[(5-methoxy-3-indoyl)ethyl]acetamide
-
-
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-[3-(1-methylindolyl)ethyl]acetamide
-
-
NADP+
-
58% residual activity at 0.5 mM NADP+
shRNA
-
shRNA1-NADK exhibits a notably higher efficiency compared with a shRNA2-NADK construct. About 70% decrease of both NADK expression, activity, and the NADPH concentration, accompanied by increased sensitivity toward H2O2
-
additional information
-
not inhibited by NADP+
-
NADH
-
may become inhibitory at very high concentrations (mM)
NADH
-
34% residual activity at 0.5 mM NADH
NADH
-
40% residual activity at 0.5 mM
NADPH
-
NADPH
-
17% residual activity at 0.5 mM NADPH
NADPH
-
66% residual activity at 0.5 mM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adenocarcinoma
NADK is activated by oncogenic signaling to sustain pancreatic ductal adenocarcinoma.
Carcinogenesis
Functional annotation of rare gene aberration drivers of pancreatic cancer.
Endometrial Neoplasms
Distinct clinical and genetic mutation characteristics in sporadic and Lynch syndrome-associated endometrial cancer in a Chinese population.
Hyperlysinemias
Clinical heterogeneity of mitochondrial NAD kinase deficiency caused by a NADK2 start loss variant.
Hyperlysinemias
Mitochondrial NADP(H) deficiency due to a mutation in NADK2 causes dienoyl-CoA reductase deficiency with hyperlysinemia.
Hypersensitivity
NADK2, an Arabidopsis chloroplastic NAD kinase, plays a vital role in both chlorophyll synthesis and chloroplast protection.
Hypersensitivity
NADK3, a novel cytoplasmic source of NADPH, is required under conditions of oxidative stress and modulates abscisic acid responses in Arabidopsis.
Mitochondrial Diseases
MNADK, a long-awaited human mitochondrion-localized NAD kinase.
nad+ kinase deficiency
Clinical heterogeneity of mitochondrial NAD kinase deficiency caused by a NADK2 start loss variant.
Neoplasms
Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs.
Neoplasms
Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data.
Neoplasms
Functional annotation of rare gene aberration drivers of pancreatic cancer.
Neoplasms
In cancer, all roads lead to NADPH.
Neoplasms
NAD+ Kinase as a Therapeutic Target in Cancer.
Nervous System Malformations
Lysine Restriction and Pyridoxal Phosphate Administration in a NADK2 Patient.
Staphylococcal Infections
From Substrate to Fragments to Inhibitor Active In Vivo against Staphylococcus aureus.
Tuberculosis
A novel fold revealed by Mycobacterium tuberculosis NAD kinase, a key allosteric enzyme in NADP biosynthesis.
Tuberculosis
Characterization of Mycobacterium tuberculosis NAD kinase: functional analysis of the full-length enzyme by site-directed mutagenesis.
Tuberculosis
Crystallization and preliminary X-ray analysis of NAD kinase from Mycobacterium tuberculosis H37Rv.
Tuberculosis
Crystallographic studies of Mycobacterium tuberculosis polyphosphate/ATP-NAD kinase complexed with NAD.
Tuberculosis
Establishment of a mass-production system for NADP using bacterial inorganic polyphosphate/ATP-NAD kinase.
Tuberculosis
First archaeal inorganic polyphosphate/ATP-dependent NAD kinase, from hyperthermophilic archaeon Pyrococcus horikoshii: cloning, expression, and characterization.
Tuberculosis
Inorganic Polyphosphate/ATP-NAD kinase of Micrococcus flavus and Mycobacterium tuberculosis H37Rv.
Tuberculosis
Molecular characterization of Escherichia coli NAD kinase.
Tuberculosis
NAD-binding mode and the significance of intersubunit contact revealed by the crystal structure of Mycobacterium tuberculosis NAD kinase-NAD complex.
Tuberculosis
NADPH regulates human NAD kinase, a NADP(+)-biosynthetic enzyme.
Tuberculosis
Overexpression, purification, and characterization of ATP-NAD kinase of Sphingomonas sp. A1.
Tuberculosis
Probing binding requirements of NAD kinase with modified substrate (NAD) analogues.
Tuberculosis
Selective inhibition of nicotinamide adenine dinucleotide kinases by dinucleoside disulfide mimics of nicotinamide adenine dinucleotide analogues.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.425
2-(adenosine-8-thio)-N-(3,4-dichlorophenethyl)acetamide
-
pH 7.4, 30°C
0.0335 - 0.335
2-(adenosine-8-thio)-N-(3-bromophenethyl)acetamide
0.2
2-(adenosine-8-thio)-N-(3-chlorophenethyl)acetamide
-
pH 7.4, 30°C
0.25
2-(adenosine-8-thio)-N-(4-bromophenethyl)acetamide
-
pH 7.4, 30°C
0.775
2-(adenosine-8-thio)-N-[(5-chloro-3-indoyl)ethyl]acetamide
-
pH 7.4, 30°C
0.13
2-[(5'-amino-5'-deoxyadenosine)-8-thio]-N-(3,4-dichlorophenethyl)acetamide
-
pH 7.4, 30°C
0.08
2-[(5'-amino-5'-deoxyadenosine)-8-thio]-N-(3-bromophenethyl)propanamide
-
pH 7.4, 30°C
0.13
2-[(5'-amino-5'-deoxyadenosine)-8-thio]-N-(4-bromophenethyl)acetamide
-
pH 7.4, 30°C
0.525
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(2-benzimidazolylethyl)acetamide
-
pH 7.4, 30°C
0.22
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(2-chloro-5-pyridyl)acetamide
-
pH 7.4, 30°C
0.14
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(2-naphthylethyl)acetamide
-
pH 7.4, 30°C
0.14
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(3,4-dichlorophenethyl)acetamide
-
pH 7.4, 30°C
0.055
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(3-bromobenzyl)acetamide
-
pH 7.4, 30°C
0.33
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(3-bromophenethyl)acetamide
-
pH 7.4, 30°C
0.02
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(3-chlorophenethyl)acetamide
-
pH 7.4, 30°C
0.3
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(3-trifluoromethylphenethyl)acetamide
-
pH 7.4, 30°C
0.08
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(4-bromophenethyl)acetamide
-
pH 7.4, 30°C
0.21
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-(4-chlorophenethyl)acetamide
-
pH 7.4, 30°C
0.35
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-phenethylacetamide
-
pH 7.4, 30°C
0.15
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-phenethylpropanamide
-
pH 7.4, 30°C
0.14
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-propargylacetamide
-
pH 7.4, 30°C
0.14
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-[(3-indoyl)ethyl]acetamide
-
pH 7.4, 30°C
0.23
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-[(4-trifluoromethyl)phenethyl]acetamide
-
pH 7.4, 30°C
0.065
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-[(5-chloro-3-indoyl)ethyl]acetamide
-
pH 7.4, 30°C
0.16
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-[(5-methoxy-3-indoyl)ethyl]acetamide
-
pH 7.4, 30°C
0.35
2-[(5'-azido-5'-deoxyadenosine)-8-thio]-N-[3-(1-methylindolyl)ethyl]acetamide
-
pH 7.4, 30°C
0.0335
2-(adenosine-8-thio)-N-(3-bromophenethyl)acetamide
-
pH 7.4, 30°C
0.335
2-(adenosine-8-thio)-N-(3-bromophenethyl)acetamide
-
pH 7.4, 30°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Lerner, F.; Niere, M.; Ludwig, A.; Ziegler, M.
Structural and functional characterization of human NAD kinase
Biochem. Biophys. Res. Commun.
288
69-74
2001
Bos taurus, Homo sapiens (O95544), Homo sapiens
brenda
Williams, M.B.; Jones, H.P.
Calmodulin-dependent NAD kinase of human neutrophils
Arch. Biochem. Biophys.
237
80-87
1985
Homo sapiens (O95544), Homo sapiens
brenda
McGuiness, E.T.; Butler, J.R.
NAD+ kinase-a review
Int. J. Biochem.
17
1-11
1985
Achromobacter aceris, Azotobacter vinelandii, Bos taurus, Columba sp., Corynebacterium ammoniagenes, Cyberlindnera jadinii, Gallus gallus, Homo sapiens (O95544), Nicotiana tabacum, Oryctolagus cuniculus, Pisum sativum, Rattus norvegicus, Saccharomyces cerevisiae, Spinacia oleracea, Triatoma infestans
brenda
Bonnac, L.; Chen, L.; Pathak, R.; Gao, G.; Ming, Q.; Bennett, E.; Felczak, K.; Kullberg, M.; Patterson, S.E.; Mazzola, F.; Magni, G.; Pankiewicz, K.W.
Probing binding requirements of NAD kinase with modified substrate (NAD) analogues
Bioorg. Med. Chem. Lett.
17
1512-1515
2007
Homo sapiens (O95544), Homo sapiens, Saccharomyces cerevisiae (P21373)
brenda
Kawai, S.; Murata, K.
Structure and function of NAD kinase and NADP phosphatase: key enzymes that regulate the intracellular balance of NAD(H) and NADP(H)
Biosci. Biotechnol. Biochem.
72
919-930
2008
Arabidopsis thaliana, Arabidopsis thaliana (Q500Y9), Arabidopsis thaliana (Q56YN3), Arabidopsis thaliana (Q9C5W3), Archaeoglobus fulgidus, Bacillus subtilis (O31612), Bacillus subtilis (O34934), Candida albicans, Columba livia, Cyberlindnera jadinii, Dictyostelium discoideum, Escherichia coli (P0A7B3), Glycine max, Homo sapiens, Homo sapiens (O95544), Lactuca sativa, Listeria monocytogenes, Methanocaldococcus jannaschii (Q58327), Micrococcus luteus (Q8VUL9), Mycobacterium tuberculosis (P9WHV7), Mycobacterium tuberculosis H37Rv (P9WHV7), Oryza sativa, Pyrococcus horikoshii (O58801), Saccharomyces cerevisiae (C7GKE4), Saccharomyces cerevisiae (P21373), Saccharomyces cerevisiae (P32622), Saccharomyces cerevisiae (Q06892), Saccharomyces cerevisiae, Salmonella enterica, Schizosaccharomyces pombe, Sorghum sp., Sphingomonas sp. A1 (Q6L7J5), Synechococcus elongatus PCC 6301, Thermotoga maritima, Triticum sp.
brenda
Pollak, N.; Niere, M.; Ziegler, M.
NAD kinase levels control the NADPH concentration in human cells
J. Biol. Chem.
282
33562-33571
2007
Homo sapiens
brenda
Ohashi, K.; Kawai, S.; Koshimizu, M.; Murata, K.
NADPH regulates human NAD kinase, a NADP+-biosynthetic enzyme
Mol. Cell. Biochem.
355
57-64
2011
Homo sapiens
brenda
Ohashi, K.; Kawai, S.; Murata, K.
Identification and characterization of a human mitochondrial NAD kinase
Nat. Commun.
3
1248
2012
Homo sapiens
brenda
Paoletti, J.; Assairi, L.; Gelin, M.; Huteau, V.; Nahori, M.A.; Dussurget, O.; Labesse, G.; Pochet, S.
8-Thioalkyl-adenosine derivatives inhibit Listeria monocytogenes NAD kinase through a novel binding mode
Eur. J. Med. Chem.
124
1041-1056
2016
Homo sapiens, Listeria monocytogenes serotype 1/2a (Q8Y8D7), Listeria monocytogenes serotype 1/2a ATCC BAA-679 (Q8Y8D7)
brenda
Rabani, R.; Cossette, C.; Graham, F.; Powell, W.S.
Protein kinase C activates NAD kinase in human neutrophils
Free Radic. Biol. Med.
161
50-59
2020
Homo sapiens (O95544), Homo sapiens
brenda
Li, B.; Wang, X.; Tai, L.; Ma, T.; Shalmani, A.; Liu, W.; Li, W.; Chen, K.
NAD kinases Metabolic targets controlling redox co-enzymes and reducing power partitioning in plant stress and development
Front. Plant Sci.
9
379
2018
Arabidopsis thaliana (Q500Y9), Arabidopsis thaliana (Q56YN3), Arabidopsis thaliana (Q9C5W3), Archaeoglobus fulgidus (P0A7B3), Bacillus subtilis (M4KX93), Escherichia coli (P0A7B3), Escherichia coli K12 (P0A7B3), Glycine max (I1KAE3), Glycine max (I1LPA7), Glycine max (I1LVA5), Glycine max (K7LNT1), Glycine max (K7LY64), Homo sapiens (O95544), Homo sapiens (Q4G0N4), Pyrococcus horikoshii (O58801), Pyrococcus horikoshii ATCC 700860 (O58801), Solanum lycopersicum (A0A3Q7E928), Solanum lycopersicum (A0A3Q7JHB9), Sphingomonas sp. (O58801), Strongylocentrotus purpuratus (C3RSF7), Strongylocentrotus purpuratus (P21373)
brenda
Hoxhaj, G.; Ben-Sahra, I.; Lockwood, S.E.; Timson, R.C.; Byles, V.; Henning, G.T.; Gao, P.; Selfors, L.M.; Asara, J.M.; Manning, B.D.
Direct stimulation of NADP+ synthesis through Akt-mediated phosphorylation of NAD kinase
Science
363
1088-1092
2019
Homo sapiens (O95544)
brenda